Anti-Durvalumab Polyclonal Antibody
Product Specifications
Background
Durvalumab (Imfinzi) is a human IgG1 monoclonal antibody that is approved by the U.S. Food and Drug Administration for the treatment of cancer. It was developed by Medimmune/AstraZeneca. Durvalumab is a programmed death-ligand 1 (PD-L1) blocking antibody which blocks the interaction of PD-L1 with the PD-1 and CD80 molecules.Antibodysystem Anti-Durvalumab Antibody, pAb, Rabbit is produced from sera of a rabbit immunized with Durvalumab.
Host
Rabbit
Immunogen
Durvalumab
Target
Rabbit polyclonal antibody to Imfinzi.
Clonality
Polyclonal
Applications
ELISA
Purification
Purified by antigen affinity column.
Form
Liquid
Buffer
0.01M PBS, pH 7.4, 50% Glycerol, 0.05% Proclin 300.
Storage Conditions
The product can be stored for 2 - 3 weeks at 2 to 8°C or for up to 12 months at -20°C. Avoid repeated freezing and thawing cycles.
Notes
Antibodysystem can customize this product per customer's request including product size, buffer components, etc. For research use only.
Specificity
The product is specific for Durvalumab. This antibody serves as an excellent positive control for Durvalumab immunogenicity (ADA) assays.
Isotype
IgG
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
CABT-ZB545 50 μl
Mouse Anti-Human SLAMF6 monoclonal antibody, clone NN21
Sign In for Pricing
View Details 
033316-APC 200 µL
CCDC28A, NT (CCDC28A, C6orf80, Coiled-coil domain-containing protein 28A, CCRL1AP) (APC) discontinued
Sign In for Pricing
View Details